A PYMNTS Company

US: CVS accused of insulin price-fixing

By  |  March 21, 2017

The leading US drugmakers and pharmacy benefit managers colluded to fix prices for insulin, leading to skyrocketing costs and windfall profits for the companies, a new lawsuit alleges. Named are the country’s three largest pharmacy benefit managers—CVS Health, Express Scripts and OptumRx—which together control 80 percent of the PBM industry and manage benefits for 180 million people.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Some of the biggest players in the American health-care industry are targeted in the 69-count class action complaint, filed March 17 in a federal court in New Jersey. Drug manufacturers Sanofi-Aventis, Novo Nordisk and Eli Lilly are included.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    “The skyrocketing cost of insulin cannot be explained away with typical drug company rationalizations for high costs,” the 300-plus page lawsuit reads. “Instead, the increased list prices are the result of a scheme and enterprise among the three dominant drug manufacturers of insulin … and the three largest Pharmacy Benefit Managers, CVS Health, Express Scripts, and OptumRx.”

    Full Content: Fierce Pharma

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.